Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01

Journal of Immunology

Volumn 192, Issue 7, 2014, Pages 2984-2993

  Yun, James ^a,b   Marcaida, Maria J ^b   Eriksson, Klara K ^a   Jamin, Heidi ^a   Fontana, Stefano ^c   Pichler, Werner J ^a   Yerly, Daniel ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Regional Blood Transfusion Service of the Swiss Red Cross St Gallen   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; BORTEZOMIB; CARBAMAZEPINE; FLUCLOXACILLIN; HLA B ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OXIPURINOL;

ARTICLE; BINDING AFFINITY; CELL ACTIVATION; CELL CLONING; CELL STIMULATION; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IMMUNOGENICITY; INCUBATION TIME; LYMPHOCYTE FUNCTION; MOLECULAR CLONING; MOLECULAR DOCKING; PRIORITY JOURNAL; T LYMPHOCYTE;

ALLOPURINOL; BINDING, COMPETITIVE; CALCIUM; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FLOW CYTOMETRY; HLA-B ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OXYPURINOL; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84897493736     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302306     Document Type: Article

References (47)

1. Halevy, S., P. D. Ghislain, M. Mockenhaupt, J. P. Fagot, J. N. Bouwes Bavinck, A. Sidoroff, L. Naldi, A. Dunant, C. Viboud, and J. C. Roujeau; EuroSCAR Study Group. 2008. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol. 58: 25-32.
2. Hung, S. I., W. H. Chung, L. B. Liou, C. C. Chu, M. Lin, H. P. Huang, Y. L. Lin, J. L. Lan, L. C. Yang, H. S. Hong, et al. 2005. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA 102: 4134-4139.
3. Lonjou, C., N. Borot, P. Sekula, N. Ledger, L. Thomas, S. Halevy, L. Naldi, J. N. Bouwes-Bavinck, A. Sidoroff, C. de Toma, et al; RegiSCAR study group. 2008. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18: 99-107.
4. Tassaneeyakul, W., T. Jantararoungtong, P. Chen, P. Y. Lin, S. Tiamkao, U. Khunarkornsiri, P. Chucherd, P. Konyoung, S. Vannaprasaht, C. Choonhakarn, et al. 2009. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 19: 704-709.
5. Kang, H. R., Y K. Jee, Y S. Kim, C. H. Lee, J. W. Jung, S. H. Kim, H. W. Park, Y S. Chang, I. J. Jang, S. H. Cho, et al; Adverse Drug Reaction Research Group in Korea. 2011. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet. Genomics 21: 303-307.
6. Khanna, D., J. D. Fitzgerald, P. P. Khanna, S. Bae, M. K. Singh, T. Neogi, M. H. Pillinger, J. Merill, S. Lee, S. Prakash, et al; American College of Rheumatology. 2012. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken) 64: 1431-1446.
7. Hershfield, M. S., J. T. Callaghan, W. Tassaneeyakul, T. Mushiroda, C. F. Thorn, T. E. Klein, and M. T. Lee. 2013. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin. Pharmacol. Ther. 93: 153-158.
8. Phillips, E. J., and S. A. Mallal. 2010. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 11: 973-987.
9. Pichler, W. J., A. Beeler, M. Keller, M. Lerch, S. Posadas, D. Schmid, Z. Spanou, A. Zawodniak, and B. Gerber. 2006. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol. Int. 55: 17-25.
10. Adam, J., W. J. Pichler, and D. Yerly. 2011. Delayed drug hypersensitivity: models of T-cell stimulation. Br. J. Clin. Pharmacol. 71: 701-707.
11. Illing, P. T., J. P. Vivian, N. L. Dudek, L. Kostenko, Z. Chen, M. Bharadwaj, J. J. Miles, L. Kjer-Nielsen, S. Gras, N. A. Williamson, et al. 2012. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486: 554-558.
12. Norcross, M. A., S. Luo, L. Lu, M. T. Boyne, M. Gomarteli, A. D. Rennels, J. Woodcock, D. H. Margulies, C. McMurtrey, S. Vernon, et al. 2012. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 26: F21-F29.
13. Ostrov, D. A., B. J. Grant, Y A. Pompeu, J. Sidney, M. Harndahl, S. Southwood, C. Oseroff, S. Lu, J. Jakoncic, C. A. de Oliveira, et al. 2012. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc. Natl. Acad. Sci. USA 109: 9959-9964.
14. Wei, C. Y., W. H. Chung, H. W. Huang, Y T. Chen, and S. I. Hung. 2012. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 129: 1562-1569.e5.
15. Ko, T. M., W. H. Chung, C. Y Wei, H. Y Shih, J. K. Chen, C. H. Lin, Y T. Chen, and S. I. Hung. 2011. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 128: 1266-1276.e11.
16. Wuillemin, N., J. Adam, S. Fontana, S. Krahenbiihl, W. J. Pichler, and D. Yerly. 2013. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. J. Immunol. 190: 4956-4964.
17. Pirmohamed, M., D. J. Naisbitt, F. Gordon, and B. K. Park. 2002. The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology 181-182: 55-63.
18. Yun, J., J. Mattsson, K. Schnyder, S. Fontana, C. R. Largiader, W. J. Pichler, and D. Yerly. 2013. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin. Exp. Allergy 43: 1246-1255.
19. Adam, J., K. K. Eriksson, B. Schnyder, S. Fontana, W. J. Pichler, and D. Yerly. 2012. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur. J. Immunol. 42: 1706-1716.
20. Marsh, S. G. E., E. D. Albert, W. F. Bodmer, R. E. Bontrop, B. Dupont, H. A. Erlich, D. E. Geraghty, J. A. Hansen, C. K. Hurley, B. Mach, et al. 2005. Nomenclature for factors of the HLA system, 2004. Tissue Antigens 65: 301-369.
21. Duraiswamy, J., J. M. Burrows, M. Bharadwaj, S. R. Burrows, L. Cooper, N. Pimtanothai, and R. Khanna. 2003. Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions. J. Virol. 77: 7401-7410.
22. Mauri-Hellweg, D., F. Bettens, D. Mauri, C. Brander, T. Hunziker, and W. J. Pichler. 1995. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J. Immunol. 155: 462-472.
23. Beeler, A., O. Engler, B. O. Gerber, and W. J. Pichler. 2006. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J. Allergy Clin. Immunol. 117: 455-462.
24. Keller, M., M. Lerch, M. Britschgi, V. Tache, B. O. Gerber, M. Lüthi, P. Lochmatter, G. Kanny, A. J. Bircher, C. Christiansen, and W. J. Pichler. 2010. Processing-dependent and -independent pathways for recognition of iodinated contrast media by specific human T cells. Clin. Exp. Allergy 40: 257-268.
25. Shimizu, Y., D. E. Geraghty, B. H. Koller, H. T. Orr, and R. DeMars. 1988. Transfer and expression of three cloned human non-HLA-A, B, C class I major histocompatibility complex genes in mutant lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 85: 227-231.
26. Irwin, J. J., and B. K. Shoichet. 2005. ZINC-a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45: 177-182.
27. Gonzalez-Galarza, F. F., S. Christmas, D. Middleton, and A. R. Jones. 2011. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 39(Database issue): D913-D919.
28. Sali, A., and T. L. Blundell. 1993. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234: 779-815.
29. Trott, O., and A. J. Olson. 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31: 455-461.
30. Bell, C. C., L. Faulkner, K. Martinsson, J. Farrell, A. Alfirevic, J. Tugwood, M. Pirmohamed, D. J. Naisbitt, and B. K. Park. 2013. T-cells from HLA-B*57: 01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms. Chem. Res. Toxicol. 26: 759-766.
31. Zanni, M. P., S. von Greyerz, B. Schnyder, K. A. Brander, K. Frutig, Y. Hari, S. Valitutti, and W. J. Pichler. 1998. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J. Clin. Invest. 102: 1591-1598.
32. Posadas, S. J., and W. J. Pichler. 2007. Delayed drug hypersensitivity reactions -new concepts. Clin. Exp. Allergy 37: 989-999.
33. Castrejon, J. L., N. Berry, S. El-Ghaiesh, B. Gerber, W. J. Pichler, B. K. Park, and D. J. Naisbitt. 2010. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J. Allergy Clin. Immunol. 125: 411-418.e4.
34. Schneider, C. H., and A. L. De Weck. 1965. A new chemical spect of penicillin allergy: the direct reaction of penicillin with epsilon-amino-groups. Nature 208: 57-59.
35. Whitaker, P., X. Meng, S. N. Lavergne, S. El-Ghaiesh, M. Monshi, C. Earnshaw, D. Peckham, J. Gooi, S. Conway, M. Pirmohamed, et al. 2011. Mass spectro-metric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. J. Immunol. 187: 200-211.
36. El-Ghaiesh, S., M. M. Monshi, P. Whitaker, R. Jenkins, X. Meng, J. Farrell, A. Elsheikh, D. Peckham, N. French, M. Pirmohamed, et al. 2012. Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis. J. Pharmacol. Exp. Ther. 341: 597-610.
37. Chessman, D., L. Kostenko, T. Lethborg, A. W. Purcell, N. A. Williamson, Z. Chen, L. Kjer-Nielsen, N. A. Mifsud, B. D. Tait, R. Holdsworth, et al. 2008. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28: 822-832.
38. Martin, A. M., C. A. Almeida, P. Cameron, A. W. Purcell, D. Nolan, I. James, J. McCluskey, E. Phillips, A. Landay, and S. Mallal. 2007. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS 21: 1233-1244.
39. Narzi, D., C. M. Becker, M. T. Fiorillo, B. Uchanska-Ziegler, A. Ziegler, and R. A. Bockmann. 2012. Dynamical characterization of two differentially disease associated MHC class I proteins in complex with viral and self-peptides. J. Mol. Biol. 415: 429-442.
40. Kosmrlj, A., E. L. Read, Y. Qi, T. M. Allen, M. Altfeld, S. G. Deeks, F Pereyra, M. Carrington, B. D. Walker, and A. K. Chakraborty. 2010. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465: 350-354.
41. Macdonald, W. A., A. W. Purcell, N. A. Mifsud, L. K. Ely, D. S. Williams, L. Chang, J. J. Gorman, C. S. Clements, L. Kjer-Nielsen, D. M. Koelle, et al. 2003. A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J. Exp. Med. 198: 679-691.
42. Archbold, J. K., W. A. Macdonald, S. Gras, L. K. Ely, J. J. Miles, M. J. Bell, R. M. Brennan, T. Beddoe, M. C. Wilce, C. S. Clements, et al. 2009. Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition. J. Exp. Med. 206: 209-219.
43. Winkler, K., A. Winter, C. Rueckert, B. Uchanska-Ziegler, and U. Alexiev. 2007. Natural MHC class I polymorphism controls the pathway of peptide dissociation from HLA-B27 complexes. Biophys. J. 93: 2743-2755.
44. Martin, A. M., D. Nolan, S. Gaudieri, C. A. Almeida, R. Nolan, I. James, F Carvalho, E. Phillips, F T. Christiansen, A. W. Purcell, et al. 2004. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. USA 101: 4180-4185.
45. Daly, A. K., P. T. Donaldson, P. Bhatnagar, Y Shen, I. Pe'er, A. Floratos, M. J. Daly, D. B. Goldstein, S. John, M. R. Nelson, et al; DILIGEN Study; International SAE Consortium. 2009. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41: 816-819.
46. Monshi, M. M., L. Faulkner, A. Gibson, R. E. Jenkins, J. Farrell, C. J. Earnshaw, A. Alfirevic, K. Cederbrant, A. K. Daly, N. French, et al. 2013. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 57: 727-739.
47. Hung, S. I., W. H. Chung, S. H. Jee, W. C. Chen, Y T. Chang, W. R. Lee, S. L. Hu, M. T. Wu, G. S. Chen, T. W. Wong, et al. 2006. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16: 297-306.